https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Target-ALS.webp8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-26 08:00:022026-08-14 11:36:51Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
Disease-modifying treatment for ALS enters Phase I